10.1038/s42255-020-00305-3 [DOI] [PMC free article] [PubMed] [Google Scholar] Deryabin Pavel I., Shatrova Alla N., Borodkina Aleksandra V
Clin Cancer Res 11 : 49124922 Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, Simon G, Fishman M, Minton S, Garrett C, Chiappori A, Lush R, Sullivan D, Daud A (2007) Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study
This imbalance is intentional
The FDA warns that CJC-1295 and BPC-157 pose a risk of immunogenicity, in which the body regards the substance as a threat and mounts an immune response against it.9 The FDA also states that the safety consequences of immunogenicity are unpredictable and include life-threatening events such as anaphylaxis.21 Your risk for immunogenicity can depend on many variables, including genetic and disease-associated factors, so you should always undergo a careful consultation and medical assessment with a licensed physician before starting a CJC-1295 or BPC-157 regimen.22 Who are muscle growth peptides for
